AVEO Announces Chairman Tuan Ha-Ngoc Steps Down

Press Release

View printer-friendly version

<<  Back

AVEO Announces Chairman Tuan Ha-Ngoc Steps Down

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 9, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced that Tuan Ha-Ngoc, after 13 years of service and leadership at AVEO, has stepped down as Chairman and a Director of the Company’s board of directors, effective November 6, 2015, to pursue interests outside the Company. Henri A. Termeer, Lead Outside Director of AVEO, has assumed Board leadership responsibilities.

“Tuan has played a fundamental role in building AVEO’s business over his long tenure at the Company,” said Mr. Termeer. “We thank him profoundly for his leadership of the Company and wish him the best in his future endeavors.”

“It has been a privilege serving in a leadership role through AVEO’s founding and development during my tenure, and contributing to its mission of improving the lives of patients with cancer and other serious unmet medical needs,” said Mr. Ha-Ngoc. “I believe that the Company’s current strategic direction, and the progress made over the last year, will help AVEO realize its full potential over the long-term.”

About AVEO

AVEO Oncology (AVEO) is a biopharmaceutical company committed to developing targeted therapies through biomarker-driven insights to provide improvements in patient outcomes where significant unmet medical needs exist. AVEO’s proprietary Human Response Platform™ has delivered unique insights into cancer and related disease biology that AVEO is seeking to leverage in the clinical development strategy of its therapeutic candidates. For more information, please visit the company’s website at www.aveooncology.com.

AVEO Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements of AVEO within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. The words “believe,” “anticipate,” “expect,” “intend,” “may,” “plan,” “could,” “should,” “seek,” or the negative of these terms or other similar expressions, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, statements about the Company’s plans, prospects and business strategies, including its goal of realizing value over the long term. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that AVEO makes due to a number of important factors, including risks relating to: AVEO’s ability to successfully implement its strategic plans; AVEO’s ability to maintain its licensing agreements; AVEO’s ability, and the ability of any licensees, to demonstrate to the satisfaction of applicable regulatory agencies the safety, efficacy and clinically meaningful benefit of AVEO’s product candidates; AVEO’s ability to successfully enroll and complete clinical trials of its product candidates; AVEO’s ability to achieve and maintain compliance with all regulatory requirements applicable to its product candidates; AVEO’s ability to obtain and maintain adequate protection for intellectual property rights relating to its product candidates and technologies; developments and expenses related to AVEO’s ongoing shareholder litigation and SEC inquiry; AVEO’s ability to raise the substantial additional funds required to achieve its goals; unplanned capital requirements; adverse general economic and industry conditions; competitive factors; and those risks discussed in the section titled “Risk Factors” in AVEO’s most recent Annual Report on Form 10-K, its quarterly reports on Form 10-Q and its other filings with the SEC. The forward-looking statements in this press release represent AVEO’s views as of the date of this press release. AVEO anticipates that subsequent events and developments may cause its views to change. While AVEO may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing AVEO’s views as of any date other than the date of this press release.

Source: AVEO Oncology

Company, Media and Investor:
Argot Partners
David Pitts, (212) 600-1902
aveo@argotpartners.com